Insmed (INSM) unit Insmed Netherlands has received marketing authorization for brensocatib, or Brinsupri, from the UK's Medicines and Healthcare Products Regulatory Agency to treat non-cystic fibrosis bronchiectasis in patients aged at least 12 years old, the regulator said Monday.

The authorization covers patients who have experienced at least two flare-ups or worsening of symptoms in the last 12 months, the MHRA said.

NCFB is a chronic, long-term condition where the airways of the lungs are damaged, leading to a cough with mucus production.